NF-κB inhibitor dehydroxymethylepoxyquinomicin suppresses osteoclastogenesis and expression of NFATc1 in mouse arthritis without affecting expression of RANKL, osteoprotegerin or macrophage colony-stimulating factor

NF-κB inhibitor dehydroxymethylepoxyquinomicin suppresses osteoclastogenesis and expression of NFATc1 in mouse arthritis without affecting expression of RANKL, osteoprotegerin or macrophage colony-stimulating factor

Inhibition of NF-κB is known to be effective in reducing both inflammation and bone destruction in animal models of arthritis. Our previous study demonstrated that a small cell-permeable NF-κB inhibitor, dehydroxymethylepoxyquinomicin (DHMEQ), suppresses expression of proinflammatory cytokines and a...

Full description

Bibliographic Details
Main Authors: Kubota, Tetsuo, Hoshino, Machiko, Aoki, Kazuhiro, Ohya, Keiichi, Komano, Yukiko, Nanki, Toshihiro, Miyasaka, Nobuyuki, Umezawa, Kazuo
Format: Online
Language:English
Published: BioMed Central 2007
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2212584/

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2212584/

Similar Items